Study on pharmacoeconomic evaluation of vericiguat in the treatment of heart failure with reduced ejection fraction

LI Feng; HE Mei; MU Lifeng; YANG Ming

doi:10.6039/j.issn.1001-0408.2023.15.15

您当前的位置：

首页 >

文章列表页 >

Study on pharmacoeconomic evaluation of vericiguat in the treatment of heart failure with reduced ejection fraction

更新时间：2023-08-10

- Study on pharmacoeconomic evaluation of vericiguat in the treatment of heart failure with reduced ejection fraction
- ZHONGGUO YAOFANG Vol. 34, Issue 15, Pages: 1869-1873(2023)
- 作者机构：
  
  川北医学院附属医院药剂科，四川南充　637000
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.15.15
  CLC： R956
- Published：15 August 2023，
  
  Received：25 December 2022，
  
  Revised：14 July 2023，
扫描看全文
黎风,何梅,母立峰等.维立西呱治疗射血分数降低的心力衰竭的药物经济学研究 ^Δ[J].中国药房,2023,34(15):1869-1873.

LI Feng,HE Mei,MU Lifeng,et al.Study on pharmacoeconomic evaluation of vericiguat in the treatment of heart failure with reduced ejection fraction[J].ZHONGGUO YAOFANG,2023,34(15):1869-1873.
黎风,何梅,母立峰等.维立西呱治疗射血分数降低的心力衰竭的药物经济学研究 ^Δ[J].中国药房,2023,34(15):1869-1873. DOI： 10.6039/j.issn.1001-0408.2023.15.15.

LI Feng,HE Mei,MU Lifeng,et al.Study on pharmacoeconomic evaluation of vericiguat in the treatment of heart failure with reduced ejection fraction[J].ZHONGGUO YAOFANG,2023,34(15):1869-1873. DOI： 10.6039/j.issn.1001-0408.2023.15.15.

摘要

目的

评估维立西呱联合标准治疗方案治疗射血分数降低的心力衰竭（HFrEF）的经济性。

方法

基于VICTORIA临床试验和相关文献数据构建三状态（包括心力衰竭稳定、心力衰竭住院和死亡状态）Markov模型。模型循环周期为1个月，模拟时限为20年，贴现率为5%。采用1倍我国2021年人均国内生产总值（GDP）作为意愿支付（WTP）阈值，对维立西呱联合标准治疗方案治疗HFrEF的经济性进行成本-效用分析，以质量调整生命年（QALY）和增量成本-效果比（ICER）作为健康产出指标。采用单因素敏感性分析和概率敏感性分析来验证基础分析结果的稳健性。

结果

维立西呱联合标准治疗方案相较于标准治疗方案的ICER为444 341.95元/QALY，高于本研究的WTP阈值（80 976元/QALY）。单因素敏感性分析结果显示，两组患者的心血管死亡转移概率对模型的稳健性影响较大，但对基础分析结果影响不大。概率敏感性分析结果显示，在本研究的WTP阈值下，维立西呱联合标准治疗方案更具经济性的概率仅有2.6%。

结论

与标准治疗方案相比，HFrEF患者使用维立西呱联合标准治疗方案不具有经济性。

Abstract

OBJECTIVE

To evaluate the cost-effectiveness of vericiguat combined with standard treatment in the treatment of heart failure with reduced ejection fraction （HFrEF）.

METHODS

Based on the results of the VICTORIA trial and related literature， a three-state （including stable state of heart failure， hospitalized state of heart failure and death state） Markov model was constructed. The cycle length was 1 month， the time horizon was 20 years， the discount rate was 5%， and one time China’s per capita gross domestic product （GDP） in 2021 was the willing-to-pay （WTP） threshold. Cost-utility analysis was performed to evaluate the cost-effectiveness of vericiguat combined with standard treatment in the treatment of HFrEF. The output indicators included quality-adjusted life year （QALY） and incremental cost-effectiveness ratio （ICER）. The robustness of the results of the basic analysis was verified by one-way sensitivity analysis and probability sensitivity analysis.

RESULTS

The ICER of vericiguat combined with the standard treatment plan compared to the standard treatment plan alone was 444 341.95 yuan/QALY， which was more than WTP of this study （80 976 yuan/QALY）. One-way sensitivity analyses showed that the probability of cardiovascular death in both groups was the main influencing parameter for the robustness of the model， but they had little influence on the results of the basic analysis. The probabilistic sensitivity analysis displayed that under the WTP threshold of this study， the possibility of vericiguat combined with the standard treatment plan being more cost-effective was 2.6%.

CONCLUSIONS

Compared with the standard treatment plan， vericiguat combined with the standard treatment plan is not cost-effective in patients with HFrEF.

关键词

维立西呱心力衰竭射血分数降低成本-效用分析Markov模型药物经济学

Keywords

heart failurereduced ejection fractioncost-utility analysisMarkov modelPharmacoeconomics

references

SAVARESE G，LUND L H. Global public health burden of heart failure[J]. Card Fail Rev，2017，3（1）：7-11.

HEIDENREICH P A，ALBERT N M，ALLEN L A，et al. Forecasting the impact of heart failure in the United States：a policy statement from the American Heart Association[J]. Circ Heart Fail，2013，6（3）：606-619.

HAO G，WANG X，CHEN Z，et al. Prevalence of heart failure and left ventricular dysfunction in China：the China Hypertension Survey，2012-2015[J]. Eur J Heart Fail，2019，21（11）：1329-1337.

COOK C，COLE G，ASARIA P，et al. The annual global economic burden of heart failure[J]. Int J Cardiol，2014，171（3）：368-376.

HUANG J，YIN H J，ZHANG M L，et al. Understanding the economic burden of heart failure in China：impact on disease management and resource utilization[J]. J Med Econ，2017，20（5）：549-553.

LAWSON C A，ZACCARDI F，SQUIRE I，et al. 20-year trends in cause-specific heart failure outcomes by sex，socioeconomic status，and place of diagnosis：a population-based study[J]. Lancet Public Health，2019，4（8）：e406-e420.

COWIE M R，ANKER S D，CLELAND J G F，et al. Improving care for patients with acute heart failure：before，during and after hospitalization[J]. ESC Heart Fail，2014，1（2）：110-145.

MARKHAM A，DUGGAN S. Vericiguat：first approval[J]. Drugs，2021，81（6）：721-726.

国家药品监督管理局. 国家药监局批准维立西呱片上市[EB/OL]. [2023-02-12]. https：//www.nmpa.gov.cn/yaowen/ypjgyw/20220519135816168.html?type=pc&m=https://www.nmpa.gov.cn/yaowen/ypjgyw/20220519135816168.html?type=pc&m=.

ARMSTRONG P W，PIESKE B，ANSTROM K J，et al. Vericiguat in patients with heart failure and reduced ejection fraction[J]. N Engl J Med，2020，382（20）：1883-1893.

HEIDENREICH P A，BOZKURT B，AGUILAR D，et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure：a report of the American College of Cardio- logy/American Heart Association joint committee on clinical practice guidelines[J]. J Am Coll Cardiol，2022，79（17）：e263-e421.

CHAN D C，HEIDENREICH P A，WEINSTEIN M C，et al. Heart failure disease management programs：a cost-effectiveness analysis[J]. Am Heart J，2008，155（2）：332-338.

桑海强，马振周，江耀辉，等. 沙库巴曲缬沙坦治疗中国射血分数降低心力衰竭患者的药物经济学评价[J]. 中国临床药理学杂志，2022，38（7）：722-726.

KRITTAYAPHONG R，PERMSUWAN U. Cost-utility analysis of add-on dapagliflozin treatment in heart failure with reduced ejection fraction[J]. Int J Cardiol，2021，322：183-190.

万一鸣，桑海强，董建增，等. 恩格列净治疗射血分数降低的心力衰竭的药物经济学评价[J]. 中国药房，2022，33（1）：74-78.

GIDWANI R，RUSSELL L B. Estimating transition pro- babilities from published evidence：a tutorial for decision modelers[J]. PharmacoEconomics，2020，38（11）：1153-1164.

国家卫生健康委员会. 中国卫生健康统计年鉴：2021[M]. 北京：中国协和医科大学出版社，2021：128.

HONG S H，LEE J Y，PARK S K，et al. The utility of 5 hypothetical health states in heart failure using time trade-off （TTO） and EQ-5D-5L in Korea[J]. Clin Drug Investig，2018，38（8）：727-736.

刘国恩. 中国药物经济学评价指南2020[M]. 北京：中国市场出版社，2020：28.

CAI D，SHI S，JIANG S，et al. Estimation of the cost-effective threshold of a quality-adjusted life year in China based on the value of statistical life[J]. Eur J Health Econ，2022，23（4）：607-615.

OCHALEK J，WANG H Y，GU Y Y，et al. Informing a cost-effectiveness threshold for health technology assessment in China：a marginal productivity approach[J]. Pharmacoeconomics，2020，38（12）：1319-1331.

韩丽珠，尹琪楠，边原，等. 2021CCS/CHFS《心力衰竭指南更新：定义新的射血分数降低心力衰竭治疗的药理学标准》解读[J]. 医药导报，2021，40（11）：1481-1486.

中华医学会老年医学分会心血管疾病学组，《老年慢性心力衰竭诊治中国专家共识》编写组. 老年人慢性心力衰竭诊治中国专家共识：2021[J]. 中华老年医学杂志，2021，40（5）：550-561.

中国老年医学学会心电及心功能分会，中国医师协会心血管内科分会，中国心衰中心联盟专家委员会. 慢性心力衰竭加重患者的综合管理中国专家共识2022[J]. 中国循环杂志，2022，37（3）：215-225.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Pharmacoeconomics of ivabradine in the treatment of CHF in the context of “Quadruple Therapy”

Cost-effectiveness of regorafenib for hepatocellular carcinoma after failure of sorafenib

Pharmacoeconomic evaluation of sugemalimab consolidation therapy for stage Ⅲ non-small cell lung cancer

Pharmacoeconomic evaluation of serplulimab combined with chemotherapy regimens for the first-line treatment of extensive-stage small-cell lung cancer

Rapid health technology assessment of Aidi injection combined with first-line chemotherapy for non-small cell lung cancer

Related Author

CHEN Congling

WU Han

ZHOU Jie

ZHANG Ruobin

ZHANG Jinping

BAO Xue

YANG Xian

HONG Wanglong

Related Institution

Dept. of Pharmacy， Nanjing Drum Tower Hospital

School of Basic Medicine and Clinical Pharmacy， China Pharmaceutical University

Dept. of Cardiology， Nanjing Drum Tower Hospital

School of Pharmacy， Anhui University of Chinese Medicine

Dept. of Pharmacy， the First Affiliated Hospital of University of Science and Technology of China （Anhui Provincial Hospital）

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰